Researchers Fine-Tune lifelong transplant medication
NCT ID NCT01435291
Summary
This study aimed to find the best dose of a key anti-rejection drug for people who have received a kidney transplant. Researchers compared how two different versions of the drug (tacrolimus) were processed by the body in 45 adult patients during the critical first three months after surgery. The goal was to use blood tests and genetic information to help doctors personalize the medication dose that patients must take long-term to prevent organ rejection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Tours Hôpital Bretonneau
Tours, France
-
CHU de Nice
Nice, 06200, France
-
CHU de Rangueil
Toulouse, France
-
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Conditions
Explore the condition pages connected to this study.